Published January 1, 2026 | Version v1

Molecular rejection signals in chronic-active T cell-mediated rejection: Histological associations and potential clinical implications

Description

Chronic-active T cell-mediated rejection (caTCMR) remains debated, and molecular diagnostics might aid risk-stratification. This retrospective two-center observational study analyzed 26 kidney allograft biopsies with caTCMR, comparing them to 40 borderline T cell-mediated rejection (bTCMR)/acute T cell-mediated rejection (aTCMR) cases (without caTCMR) and 308 subthreshold/negative controls after excluding microvascular inflammation at/above threshold and overlapping pathologies. All biopsies received transcriptomic evaluation through microarray-based gene expression profiling. caTCMR cases with aTCMR (n = 8) showed higher molecular T cell-mediated rejection (TCMR) activity (median probability of molecular TCMR [TCMRprob] 0.54 [0.30-0.83]) than "pure" caTCMR (n = 11; TCMRprob 0.03 [0.01-0.28], P = .012) or caTCMR with bTCMR (n = 7; TCMRprob 0.01 [0.01-0.77], P = .036). TCMRprob was low in subthreshold/negative controls but elevated in aTCMR, BK-virus nephropathy and pyelonephritis cases (side cohort). Molecular sign-outs classified 4 of 11 (36%) "pure" caTCMR cases as molecular TCMR. Within the TCMR continuum (26 caTCMR plus 40 bTCMR/aTCMR), interstitial inflammation, tubulitis, and total inflammation-lesions were associated in univariable analyses with TCMRprob >0.2, while interstitial inflammation in areas of interstitial fibrosis and tubular atrophy/tubulitis in areas of interstitial fibrosis and tubular atrophy correlated with molecular chronicity. Seven of 26 (27%) caTCMR and 7 of 40 (18%) bTCMR/aTCMR cases showed mixed molecular rejection activity above thresholds. In conclusion, significant molecular TCMR activity was present in a subset of caTCMR cases and was associated with higher inflammation/tubulitis/total inflammation scores and, at times, molecular antibody-mediated rejection signals, even with microvascular inflammation <2. To confirm these preliminary observations, future studies and external validation are needed.

Notes

Supported by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) - Funded by the European Union – Next Generation EU.

Files

1-s2.0-S1600613525034586-main.pdf

Files (6.8 MB)

Name Size Download all
md5:e243340875561546e18781d01f1501c7
6.8 MB Preview Download

Additional details

Related works

Has metadata
41513042 (PMID)
Is part of
1600-6135 (ISSN)
1600-6143 (ISSN)
References
10.1016/j.ajt.2025.12.288 (DOI)